http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Jessie Y. Li,Melissa R. Young,Gloria Huang,Babak Litkouhi,Alessandro Santin,Peter E. Schwartz,Shari Damast 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.4
Objective: To examine outcomes in a modern treatment era for stage III uterine serouscarcinoma (USC). Methods: Fifty women were retrospectively identified as 2009 International Federation ofGynecology and Obstetrics stage III USC patients who received radiotherapy (RT) at ourinstitution between 1/2003–5/2018. The patients were divided into 2 cohorts: 20 in the earlyera (2003–2010) and 30 in the modern era (2011–2018). Patient characteristics were comparedusing χ2tests for categorical variables and t-tests for continuous variables. Recurrence freesurvival (RFS) and overall survival (OS) were analyzed with Kaplan-Meier estimates, the log rank test, and Cox proportional hazards. Results: The modern era differed from the early era in the increased use of volume-directedexternal beam RT (EBRT) as opposed to vaginal brachytherapy (VB) alone (33.3% vs 5.0%,p=0.048), minimally invasive surgery (56.7% vs. 25%, p=0.027), sentinel node sampling(26.7% vs. 0%, p=0.012), computed tomography imaging in the perioperative period (63.3%vs. 30%, p=0.044), and human epidermal growth factor receptor 2/neu testing (96.7% vs. 55%, p=0.001). Median follow-up for early and modern eras was 37.27 and 33.23 months,respectively. The early vs. modern 3-year RFS was 33% and 64% (p=0.039), respectively, whilethe 3-year OS was 55% and 90% (p=0.034). Regional nodal recurrence more common amongthe patients who received VB only (p=0.048). Conclusion: Modern era treatment was associated with improved RFS and OS in patientswith stage III USC. Regional nodal recurrences were significantly reduced in patients whoreceived EBRT
Jessie Y. Li,Christopher K. Arkfeld,Joan Tymon-Rosario,Emily Webster,Peter Schwartz,Shari Damast,Gulden Menderes 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.2
Objective: To evaluate prognostic factors, outcomes, and management patterns of patients treated for squamous cell carcinoma of the vulva. Methods: One hundred sixty-four women were retrospectively identified with primary squamous cell carcinoma of the vulva treated at our institution between 1/1996–12/2018. Descriptive statistics were performed on patient, tumor, and treatment characteristics. The χ2 tests and t-tests were used to compare categorical variables and continuous variables, respectively. Recurrence free survival (RFS), overall survival (OS), and disease-specific survival (DSS) were analyzed with Kaplan-Meier estimates, the log-rank test, and Cox proportional hazards. Results: Median follow-up was 52.5 months. Five-year RFS was 67.9%, 60.0%, 42.1%, and 20.0% for stage I–IV, respectively. Five-year DSS was 86.2%, 81.6%, 65.0%, and 42.9% for stage I–IV, respectively. On multivariate analysis, positive margins predicted overall RFS (hazard ratio [HR]=3.55; 95% confidence interval [CI]=1.18–10.73; p=0.025), while presence of lichen sclerosus on pathology (HR=2.78; 95% CI=1.30–5.91; p=0.008) predicted local RFS. OS was predicted by nodal involvement (HR=2.51; 95% CI=1.02–6.13; p=0.043) and positive margins (HR=5.19; 95% CI=2.03–13.26; p=0.001). Adjuvant radiotherapy significantly improved RFS (p=0.016) and DSS (p=0.012) in node-positive patients. Median survival after treatment of local, groin, and pelvic/distant recurrence was 52, 8, and 5 months, respectively. Conclusion: For primary treatment, more conservative surgical approaches can be considered with escalation of treatment in patients with concurrent precursor lesions, positive margins, and/or nodal involvement. Further studies are warranted to improve risk stratification in order to optimize treatment paradigms for vulvar cancer patients.